EYP-1901 shows continued safety for wet AMD treatment

NEW YORK — In this Healio Video Perspective from the ASRS meeting, Nancy Lurker, CEO of EyePoint Pharmaceuticals, announces the 12-month results from the DAVIO clinical trial of EYP-1901 for wet age-related macular degeneration.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

”
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

American Society of Retina Specialists Meeting